Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
Learn more about:
Related Clinical Trial
QST for Corneal Nerve Function
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Topical Insulin – Utility and Results in Neurotrophic Keratopathy Types 2 and 3
Corneal Nerves After Treatment With Cenegermin
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
Nerve Growth Factor for the Treatment of Cornea Disease
Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Miniinvasive Corneal Neurotization. A Pilot Study.
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1